

# TABLE OF CONTENTS

## CHAPTER 1

### Introduction

## CHAPTER 2

### State Common Law Claims Based Upon Informational Defects

§ 2.01	Introduction . . . . .	2.01-2
§ 2.02	The Duty to Warn and Unavoidably Unsafe Product Doctrine . . . . .	2.02-1
[1]	Unavoidably Unsafe Products and Design Defects . . . . .	2.02-15
[2]	Prescription Medical Devices and Biologics as Unavoidably Unsafe Products . . . . .	2.02-16
[3]	Case-by-Case Versus Categorical Application of the Unavoidably Unsafe Product Doctrine . . . . .	2.02-26
§ 2.03	The Learned Intermediary Rule . . . . .	2.03-1
[1]	The Learned Intermediary Rule as the Distinctive Attribute of Litigation Involving Prescription Medical Products . . . . .	2.03-3
[2]	Who Is the Learned Intermediary? . . . . .	2.03-69
[3]	Exceptions to the Learned Intermediary Rule . . . . .	2.03-79
[a]	Over-the-Counter Drugs . . . . .	2.03-79
[b]	Mass Immunization Exception . . . . .	2.03-81
[c]	FDA-Mandated Patient Warning Exception . . . . .	2.03-85
[d]	Personal Choice Product Exception . . . . .	2.03-88
[e]	Direct-to-Consumer Marketing Exception . . . . .	2.03-92

	[f] FDA Recall Exception . . . . .	2.03-96
	[g] Financial and Other Prescriber Incentives Exception . . . . .	2.03-97
	[h] Miscellaneous Unrecognized Exceptions . . . . .	2.03-100
§ 2.04	Adequacy of Warnings . . . . .	2.04-1
	[1] Pleading Requirements for Warnings Adequacy . . . . .	2.04-1
	[2] Criteria for an Adequate Warning . . . . .	2.04-5
	[3] Establishing the Adequacy of a Warning as a Matter of Law . . . . .	2.04-72
§ 2.05	Establishing Causation in a Warning Case . . . . .	2.05-1
	[1] Pleading Requirements for Warning Causation . . . . .	2.05-1
	[2] When an Inadequate Warning Is Non-Causal . . . . .	2.05-4
	[3] Issues of Fact Concerning Warning Causation . . . . .	2.05-62
	[4] The Presumption That an Inadequate Warning Is Causal . . . . .	2.05-79
	[5] Other Causation Issues in Warning Cases . . . . .	2.05-97
	[6] Miscellaneous Causation Issues in Warning Claims . . . . .	2.05-115
§ 2.06	Overpromotion and Negligent Marketing Claims . . . . .	2.06-1
§ 2.07	Implied Warranty Claims . . . . .	2.07-1
§ 2.08	Express Warranty Claims . . . . .	2.08-1
§ 2.09	Illegal Promotion and Marketing Claims . . . . .	2.09-1
§ 2.10	Duty to Warn Claims Involving Direct Patient Warnings . . . . .	2.10-1
§ 2.11	Warning Claims Brought by Prescribing Physicians . . . . .	2.11-1
§ 2.12	Public Policy Considerations Underlying the Unavoidable Unsafe Product Doctrine and the Learned Intermediary Rule . . . . .	2.12-1
§ 2.13	Fraud/Intentional Misrepresentation . . . . .	2.13-1
§ 2.14	Negligent Misrepresentation . . . . .	2.14-1
§ 2.15	State Consumer Protection Acts . . . . .	2.15-1
§ 2.16	Federal RICO Claims . . . . .	2.16-1

**CHAPTER 3**

**State Common Law Claims Based Upon  
Non-Informational Defects**

§ 3.01	Introduction—Design Defect Claims . . . . .	3.01-2
§ 3.02	Claims Sounding In Strict Liability . . . . .	3.02-1
	[1] Strict Liability—Pleading and Merger of Other Causes of Action . . . . .	3.02-3
	[2] Elements of Strict Liability Claims Brought Under <i>The Restatement</i> ( <i>Second</i> ) of <i>Torts</i> § 402A . . . . .	3.02-12
	[3] Requirement of an Unreasonably Dangerous Product . . . . .	3.02-17
	[a] Consumer Expectations Test . . . . .	3.02-21
	[b] Risk-Utility Test . . . . .	3.02-28
	[c] Hybridization of Consumer Expectations and Risk-Utility Tests . . . . .	3.02-41
	[d] The Role of the Feasible Safer Alternative Design . . . . .	3.02-45
	[e] Injury Alone Is Not Sufficient to Establish an Unreasonably Dangerous Product . . . . .	3.02-70
	[4] The Unavoidably Unsafe Product Doctrine . . . . .	3.02-76
	[a] Relationship of the Unavoidably Unsafe Product Doctrine to Design Defect Claims . . . . .	3.02-76
	[b] Role of the Risk-Utility Test Under the Unavoidably Unsafe Product Doctrine . . . . .	3.02-91
	[c] Role of Feasible Safer Alternative Design Under the Unavoidably Unsafe Product Doctrine . . . . .	3.02-94
	[5] Requirements of Injury and Proximate Cause . . . . .	3.02-97
§ 3.03	Design Defect Claims Under the <i>Restatement</i> ( <i>Third</i> ) of <i>Torts: Products Liability</i> . . . . .	3.03-1
§ 3.04	Design Defect Claims Sounding in Negligence . . . . .	3.04-1
§ 3.05	Manufacturing Defects . . . . .	3.05-1
	[1] Introduction . . . . .	3.05-1
	[2] The <i>Restatement</i> Formulation of Manufacturing Defect . . . . .	3.05-15
	[3] Plaintiff’s Prima Facie Manufacturing Defect Case . . . . .	3.05-18

	[4] Rebutting Plaintiff's <i>Prima Facie</i> Case of Manufacturing Defect . . . . .	3.05-28
§ 3.06	Medical Monitoring . . . . .	3.06-1
§ 3.07	Independent Duty to Test . . . . .	3.07-1
§ 3.08	Market Share Liability . . . . .	3.08-1
§ 3.09	Cognizable Injury . . . . .	3.09-1
§ 3.10	Miscellaneous Claims . . . . .	3.10-1
	[1] Duty to Recall . . . . .	3.10-1
	[2] Restitution/Unjust Enrichment . . . . .	3.10-6
	[3] Lanham Act . . . . .	3.10-18
	[4] Redhibition . . . . .	3.10-18
	[5] Failure to Train . . . . .	3.10-21
	[6] Intentional/Negligent Infliction of Emotional Distress . . . . .	3.10-23
	[7] Miscellaneous Federal Claims . . . . .	3.10-28
	[8] Miscellaneous State Law Claims . . . . .	3.10-32

## CHAPTER 4

### The Federal Framework

§ 4.01	What Litigators Need to Know About the FDA . . . . .	4.01-2
	[1] Introduction . . . . .	4.01-2
	[2] FDA Approval Processes for Prescription Medical Products . . . . .	4.01-3
	[a] Prescription Drugs . . . . .	4.01-9
	[b] Medical Devices . . . . .	4.01-24
	[c] Generic Drugs . . . . .	4.01-35
	[d] Biologics . . . . .	4.01-37
	[e] Biosimilars . . . . .	4.01-37
	[f] Combination Products . . . . .	4.01-39
	[3] Post-Approval FDA Regulation . . . . .	4.01-40
	[4] Off-Label Use . . . . .	4.01-54
§ 4.02	The Food, Drug and Cosmetic Act as a Source of Substantive Tort Law . . . . .	4.02-1
	[1] No Private Food, Drug and Cosmetic Act Right of Action . . . . .	4.02-1
	[2] Negligence <i>Per Se</i> and Related Doctrines . . . . .	4.02-12
	[a] General Negligence <i>Per Se</i> Principles Applicable to Prescription Medical Product Liability Litigation . . . . .	4.02-12
	[b] The Viability of Negligence <i>Per Se</i> Claims Based Upon Allegations of FDCA Violations . . . . .	4.02-26

	[i] Arguments in Favor of Allowing FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-27
	[ii] Arguments in Favor of Rejecting FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-33
[3]	Defenses to FDCA-Based Negligence <i>Per Se</i> Claims . . . . .	4.02-50
	[a] Defense on the Merits/No Violation . . . . .	4.02-50
	[b] Non-Statutory Violations. . . . .	4.02-54
	[c] Imposition of Novel Duties. . . . .	4.02-59
	[d] Allegations Concerning the FDA Approval Process. . . . .	4.02-68
	[e] Violations of Vague or Generic Enactments. . . . .	4.02-72
	[f] Causation Issues in FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-79
§ 4.03	Impact of Medicare Secondary Payer Legislation . . . . .	4.03-1

**CHAPTER 5**

**Federal Preemption as a Defense to Drug and  
Medical Device Litigation**

§ 5.01	Express Preemption. . . . .	5.01-4
	[1] General Considerations Concerning Express Preemption . . . . .	5.01-4
	[2] Application of Express Preemption to Common Law Tort Claims . . . . .	5.01-8
	[3] Express Preemption and Medical Devices. . . . .	5.01-10
	[a] Express Preemption and Substantially Equivalent Devices: <i>Lohr</i> and its Progeny . . . . .	5.01-11
	[b] Express Preemption and Premarket Approved Devices: <i>Riegel</i> and its Progeny . . . . .	5.01-18
	[c] Express Preemption Issues Following <i>Riegel</i> and <i>Lohr</i> . . . . .	5.01-20
	[i] Preemption Issues Involving Multi-Component Device Systems . . . . .	5.01-33

**DRUG AND MEDICAL DEVICE DESKBOOK**

	[ii]	Violation, “Identity of Requirements,” or “Parallel” Claims . . . . .	5.01-37
	[iii]	Effect of Off-Label Use/Promotion on Preemption . . . . .	5.01-82
	[iv]	Other Claims Not Addressed by the Supreme Court . . . . .	5.01-92
	[v]	Procedural and Pleading Issues Relating to PMA Medical Device Preemption . . . . .	5.01-107
	[d]	Express Preemption and Devices on the Market Through Other FDA Procedures . . . . .	5.01-131
	[i]	Investigational Devices . . . . .	5.01-131
	[ii]	PMA Supplement Devices . . . . .	5.01-138
	[iii]	Product Development Protocol and Transitional Devices . . . . .	5.01-140
	[iv]	Downclassified Devices . . . . .	5.01-141
	[v]	Reclassified Devices . . . . .	5.01-141
	[vi]	Combination Devices . . . . .	5.01-141
	[vii]	Humanitarian Devices . . . . .	5.01-142
	[e]	Special Cases of Device-Specific Preemption by Regulation . . . . .	5.01-142
	[i]	Tampon Warnings . . . . .	5.01-142
	[ii]	Latex Glove Warnings . . . . .	5.01-145
	[iii]	Contact Lens Care Products . . . . .	5.01-147
	[iv]	Latex Condoms . . . . .	5.01-147
[4]		Express Preemption and Prescription Drugs . . . . .	5.01-147
[5]		Express Preemption and Vaccines . . . . .	5.01-148
[6]		Express Preemption and Monograph (OTC) Drugs . . . . .	5.01-152
[7]		Express Preemption and FDA Decisions Not to Regulate . . . . .	5.01-160
[8]		Express Preemption and Informed Consent . . . . .	5.01-161
[9]		Express Preemption and the PREP Act . . . . .	5.04-162
[10]		Express Preemption and Discovery . . . . .	5.01-162
§ 5.02		Implied Preemption . . . . .	5.02-1
	[1]	Field Preemption . . . . .	5.02-1
	[2]	Conflict Preemption . . . . .	5.02-3
	[a]	Conflict Preemption by Reason of Impossibility . . . . .	5.02-3

TABLE OF CONTENTS

	[b] Conflict Preemption by Reason of Obstruction. . . . .	5.02-5
[3]	Implied Preemption in Product Liability Litigation . . . . .	5.02-6
	[a] Effect on Implied Preemption of Express Preemption Clauses . . . . .	5.02-6
	[b] Effect on Implied Preemption of Express Saving Clauses . . . . .	5.02-8
[4]	Implied Conflict Preemption in the FDCA Context . . . . .	5.02-9
	[a] Prescription Drug Labeling and Marketing. . . . .	5.02-9
	[i] Background . . . . .	5.02-9
	[ii] The 2006 FDA Preemption Preamble . . . . .	5.02-13
	[iii] <i>Wyeth v. Levine</i> . . . . .	5.02-17
	[iv] <i>Merck Sharp &amp; Dohme Corp. v. Albrecht</i> . . . . .	5.02-20
	[v] Implied Preemption of Tort Claims Involving Prescription Drugs After <i>Levine</i> and <i>Albrecht</i> . . . . .	5.02-24
	[vi] Preemption Based on Likely or Actual FDA Rejection of the Relevant Warning. . . . .	5.02-32
	[vii] Preemption Based on Unavailability of CBE/FDA Prior Review Requirement. . . . .	5.02-53
	[viii] Preemption Based on Interference with the FDCA Regulatory Scheme. . . . .	5.02-80
	[b] Generic Drugs . . . . .	5.02-83
	[c] Fraud on the FDA . . . . .	5.02-111
	[d] Private FDCA Enforcement Violation Claims . . . . .	5.02-135
	[e] Miscellaneous Implied Preemption Situations . . . . .	5.02-152
	[i] Boxed Warnings . . . . .	5.02-152
	[ii] Off-label Promotion . . . . .	5.02-153
	[iii] Failure to Report to/Warn the FDA. . . . .	5.02-157
	[iv] Monograph (OTC) Drugs . . . . .	5.02-168
	[v] Other Claims . . . . .	5.02-169
§ 5.03	Complete Preemption and Federal Question Jurisdiction . . . . .	5.03-1

## CHAPTER 6

### Before Litigation Starts: Enhancing Chances for Success

§ 6.01	Introduction . . . . .	6.01-2
§ 6.02	From the Plaintiff's Perspective . . . . .	6.02-1
	[1] Factual and Legal Investigation . . . . .	6.02-1
	[2] The Internet . . . . .	6.02-2
	[a] Government Web Sites . . . . .	6.02-2
	[b] Nongovernment Web Sites . . . . .	6.02-4
§ 6.03	From the Defendant's Perspective . . . . .	6.03-1
	[1] Prophylactic Planning . . . . .	6.03-1
	[a] SOPs . . . . .	6.03-2
	[b] Document Management . . . . .	6.03-2
	[c] Regulatory and Good Clinical Practice Issues . . . . .	6.03-4
	[d] Review of Internal and External Documents . . . . .	6.03-4
	[e] Freedom of Information Act . . . . .	6.03-5
	[f] Marketing Issues . . . . .	6.03-5
	[2] Adverse Event Reporting . . . . .	6.03-7
	[3] Duty to Update Labeling . . . . .	6.03-10
	[a] Section 10 of the <i>Restatement</i> ( <i>Third</i> ) of <i>Torts</i> . . . . .	6.03-12
	[b] Other Causes of Action . . . . .	6.03-12
	[4] Duty to Warn Regarding Off-Label Use . . . . .	6.03-13
	[5] Recalls . . . . .	6.03-14
	[a] Consequences . . . . .	6.03-15
	[b] Planning for and Executing Recalls . . . . .	6.03-16
	[6] Clinical Studies . . . . .	6.03-18
	[a] Clinical Trial Registry . . . . .	6.03-19
	[b] Integrated Pharmaceutical Networks . . . . .	6.03-20
	[c] International Clinical Studies . . . . .	6.03-21
	[d] Remuneration . . . . .	6.03-21
	[e] Consent . . . . .	6.03-22
	[f] Termination of Clinical Studies . . . . .	6.03-25
	[7] "Expanded Access" . . . . .	6.03-27

## CHAPTER 7

### Class Actions

§ 7.01	Overview . . . . .	7.01-3
§ 7.02	Nature of the Certification Determination . . . . .	7.02-1



TABLE OF CONTENTS

xiii

§ 7.03	Class Actions in Personal Injury Cases . . . . .	7.03-1
	[1] Tolling of the Statute of Limitations. . . . .	7.03-1
	[2] Settlement . . . . .	7.03-4
§ 7.04	Class Actions for Economic Loss . . . . .	7.04-1
	[1] Causes of Action . . . . .	7.04-1
	[2] Grounds for Dismissal of a Claim . . . . .	7.04-3
	[a] Injury in Fact . . . . .	7.04-3
	[b] Factual Causation. . . . .	7.04-5
	[c] Proximate Causation . . . . .	7.04-6
§ 7.05	The Elements of a Definable and Ascertainable Class Under Rule 23(a) . . . . .	7.05-1
	[1] Numerosity . . . . .	7.05-2
	[2] Commonality. . . . .	7.05-4
	[3] Typicality . . . . .	7.05-5
	[4] Adequacy of Representation . . . . .	7.05-11
§ 7.06	Criteria for Determining Whether a Mandatory Class Action Can Be Maintained Under Rule 23(b)(1) or Rule 23(b)(2) . . . . .	7.06-1
	[1] Overview. . . . .	7.06-1
	[2] Constitutional Issues. . . . .	7.06-2
	[3] Classes Based on Declaratory or Injunctive Relief Under Rule 23(b)(1)(A) . . . . .	7.06-4
	[4] The “Limited Fund” Class Under Rule 23(b)(1)(B). . . . .	7.06-5
	[5] Medical Monitoring Classes Under Rule 23(b)(2) . . . . .	7.06-9
	[a] Medical Monitoring as Final Injunctive Relief . . . . .	7.06-10
	[b] Money Damages Cannot Predominate in Rule 23(b)(2) Class. . . . .	7.06-13
	[c] The Proposed Class Must Be Cohesive. . . . .	7.06-15
§ 7.07	Rule 23(b)(3) and Requirements of Predominance and Superiority . . . . .	7.07-1
	[1] Predominance . . . . .	7.07-1
	[a] Problems Inherent in Proposed Nationwide Classes . . . . .	7.07-1
	[b] Other Individual Issues . . . . .	7.07-4
	[2] Superiority. . . . .	7.07-6
	[3] Manageability . . . . .	7.07-10
§ 7.08	The Potential for Certification on a Particular Issue. . . . .	7.08-1

§ 7.09	Federal Jurisdiction Over Class Actions—The Class Action Fairness Act (CAFA) . . . . .	7.09-1
	[1] Overview . . . . .	7.09-1
	[2] Existing Federal Question and Diversity Jurisdiction Unchanged . . . . .	7.09-1
	[3] Grounds for Diversity Jurisdiction . . . . .	7.09-3
	[a] \$5 Million Amount in Controversy Requirement . . . . .	7.09-3
	[b] Minimal Diversity Requirements . . . . .	7.09-5
	[c] CAFA Applies to Suits with More Than 100 Plaintiffs . . . . .	7.09-9
	[4] Changes in Rules When Removing Class Actions . . . . .	7.09-11
	[5] Appellate Review of Remand Orders . . . . .	7.09-11
§ 7.10	Settlements of Class Actions . . . . .	7.10-1
	[1] Overview . . . . .	7.10-1
	[2] Judicial Scrutiny of Class Action Settlements Under CAFA . . . . .	7.10-1
	[3] Enhanced Judicial Scrutiny of Class Action Settlements Generally . . . . .	7.10-2
	[4] Required Notice of Class Settlement . . . . .	7.10-3
§ 7.11	Canadian Pharmaceutical and Medical Device Class Action . . . . .	7.11-1
	[1] Overview . . . . .	7.11-1
	[2] Certification Criteria . . . . .	7.11-2
	[a] “Identifiable Class” . . . . .	7.11-3
	[b] “Common Issues” Requirement . . . . .	7.11-4
	[c] “Preferable Procedure” . . . . .	7.11-4
	[d] Adequate “Representative Plaintiff” . . . . .	7.11-5
	[3] Settlement Considerations—Opt-In vs. Opt-Out Classes . . . . .	7.11-6

## CHAPTER 8

### Non-Manufacturer Defendants in Drug and Medical Device Litigation

§ 8.01	Introduction . . . . .	8.01-3
§ 8.02	Commercial Distributors . . . . .	8.02-1
	[1] General Rule of Strict Liability . . . . .	8.02-1
	[2] <i>Restatement (Third)</i> Position . . . . .	8.02-8
	[3] Statutory Exceptions to Strict Liability . . . . .	8.02-9
	[4] Overprescription Theories . . . . .	8.02-13
	[5] Miscellaneous Intermediate Product Handler . . . . .	8.02-16

TABLE OF CONTENTS

§ 8.03 Pharmacists . . . . . 8.03-1

    [1] Majority Rule Rejecting Product Liability  
        Claims Against Pharmacists for  
        Prescribed Drugs . . . . . 8.03-1

    [2] Minority Rule Allowing Product Liability  
        Claims Against Pharmacists . . . . . 8.03-20

    [3] Exceptional Circumstances Justifying  
        Imposition of Liability on Pharmacists . . . . . 8.03-24

        [a] Obvious Inadequacies on Face of  
            Prescription/Failure to Label  
            Properly . . . . . 8.03-25

        [b] Voluntary Assumption of Duty  
            to Warn . . . . . 8.03-27

        [c] Specific Knowledge of the  
            Characteristics of a  
            Patient/Customer . . . . . 8.03-29

        [d] Failure to Warn of Adverse  
            Interaction of Two Prescribed  
            Drugs . . . . . 8.03-30

        [e] Dispensing Without Valid  
            Prescription . . . . . 8.03-31

        [f] Failure to Provide FDA-Mandated  
            Materials . . . . . 8.03-31

        [g] Overprescription Theories . . . . . 8.03-32

§ 8.04 Bulk and Component Part Sellers . . . . . 8.04-1

    [1] General Rule . . . . . 8.04-1

    [2] Federal Law Considerations . . . . . 8.04-3

    [3] Common Law Considerations . . . . . 8.04-8

§ 8.05 Hospitals . . . . . 8.05-1

    [1] Strict Liability . . . . . 8.05-1

        [a] *Restatement* Position and the  
            Sale-Service Distinction . . . . . 8.05-1

        [b] Implied Warranty . . . . . 8.05-7

    [2] Public Policy Based Rationales for  
        Limiting Hospital Product Liability . . . . . 8.05-10

    [3] Informed Consent . . . . . 8.05-13

        [a] No Separate Duty . . . . . 8.05-13

        [b] Assumption of Duty . . . . . 8.05-20

    [4] Negligence . . . . . 8.05-21

    [5] Miscellaneous . . . . . 8.05-22

§ 8.06 Physicians and Similar Health Care Providers . . . . . 8.06-1

    [1] Strict Liability/Breach of  
        Implied Warranty . . . . . 8.06-1

    [2] Informed Consent . . . . . 8.06-7

        [a] FDA Regulatory Status . . . . . 8.06-7

	[b] Conflict Of Interest . . . . .	8.06-9
	[c] Lacking Expert Opinion . . . . .	8.06-10
§ 8.07	Participants in Clinical Trials . . . . .	8.07-1
	[1] Monitoring . . . . .	8.07-1
	[2] Conflicts of Interest . . . . .	8.07-3
	[3] Product Liability . . . . .	8.07-4
§ 8.08	Promoters and Co-Promoters . . . . .	8.08-1
	[1] Wrongful Marketing or Promotion . . . . .	8.08-1
	[2] First Amendment Defense . . . . .	8.08-5
	[3] Co-Promoters . . . . .	8.08-8
	[4] Marketing Consultants . . . . .	8.08-9
§ 8.09	Original Patent Holders and Inventors . . . . .	8.09-1
§ 8.10	The Food and Drug Administration and Other Standards-Setting Organizations . . . . .	8.10-1
§ 8.11	Parents, Subsidiaries and Successors . . . . .	8.11-1
§ 8.12	Manufacturer Sales Representatives and Other Personnel . . . . .	8.12-1
§ 8.13	Publishers . . . . .	8.13-1
§ 8.14	Reprocessors, Repackagers and Relabelers . . . . .	8.14-1
§ 8.15	Retailers . . . . .	8.15-1
§ 8.16	Non-profit Patient Assistance Programs . . . . .	8.16-1

## CHAPTER 9

### Issues in the Management of the Litigation

§ 9.01	Overview . . . . .	9.01-3
§ 9.02	Procedural Aggregation . . . . .	9.02-1
	[1] Initiation of Claims . . . . .	9.02-1
	[2] Joinder of Plaintiffs . . . . .	9.02-4
§ 9.03	Collateral Estoppel . . . . .	9.03-1
§ 9.04	Removal from State Court to Federal Court . . . . .	9.04-1
	[1] Introduction . . . . .	9.04-1
	[2] General Principles of Removal . . . . .	9.04-1
	[3] Removal in Diversity Cases . . . . .	9.04-3
	[4] Removal in Federal Question Cases . . . . .	9.04-11
	[5] Federal Officer Removal . . . . .	9.04-15
§ 9.05	Multidistrict Litigation . . . . .	9.05-1
	[1] The Commencement of Multidistrict Litigation . . . . .	9.05-1
	[2] Requirement that Actions to be Transferred Have Common Questions of Fact . . . . .	9.05-7
	[a] All Actions Before the Panel Must Have One or More Questions of Fact in Common . . . . .	9.05-7

**TABLE OF CONTENTS**

xvii

	[b] The Questions of Fact in Common Must Lend Themselves to Resolution Through Centralization . . . . .	9.05-8
	[c] Commonality Cannot Be Insufficiently Complex . . . . .	9.05-9
	[d] Transfer Must Be for the Convenience of the Parties and Witnesses . . . . .	9.05-10
	[e] Transfer Must Promote the Just and Efficient Conduct of Pretrial Proceedings. . . . .	9.05-12
[3]	Remand of Actions at Suggestion of Transferee Court. . . . .	9.05-14
[4]	Discovery Issues in Multidistrict and Multi-Plaintiff Proceedings . . . . .	9.05-15
	[a] Introduction—The Beginning of a Multidistrict Litigation . . . . .	9.05-15
	[b] Discovery of Defendants. . . . .	9.05-17
	[i] Document Preservation and Production . . . . .	9.05-17
	[ii] Other Discovery Issues. . . . .	9.05-20
	[c] Discovery of Plaintiffs. . . . .	9.05-23
	[d] Case-Specific Expert Discovery Within an MDL. . . . .	9.05-29
	[e] Protecting Trade Secrets and Other Confidential Information. . . . .	9.05-31
	[i] Drafting a Confidentiality Order . . . . .	9.05-34
	[ii] Breach of a Confidentiality Order . . . . .	9.05-41
§ 9.06	Discovery of the FDA . . . . .	9.06-1
§ 9.07	Relations Between State and Federal Courts. . . . .	9.07-1
	[1] Introduction. . . . .	9.07-1
	[2] The All Writs Act and the Anti-Injunction Act . . . . .	9.07-2
	[3] Injunctions in Aid of Jurisdiction . . . . .	9.07-2
	[4] Injunctions to Protect a Federal Court Judgment . . . . .	9.07-5

**CHAPTER 10**

**Expert Witnesses**

§ 10.01	Introduction . . . . .	10.01-2
§ 10.02	Types of Experts . . . . .	10.02-1

§ 10.03	Discovery and Evaluation of Experts . . . . .	10.03-1
	[1] Introduction . . . . .	10.03-1
	[a] Federal Rules Relating to Discovery of Experts . . . . .	10.03-2
	[b] State Rules Relating to Discovery of Experts . . . . .	10.03-4
	[c] Discovery of Draft Expert Reports and Counsel's Communications with Experts . . . . .	10.03-7
	[d] Discovery of Counsel's Communications with the Expert . . .	10.03-10
	[2] Protecting Experts from Unnecessary Disclosure . . . . .	10.03-12
	[a] Communications between Counsel and Experts . . . . .	10.03-12
	[b] Communications among Experts . . . .	10.03-13
	[c] Withdrawal of the Testifying Expert . .	10.03-13
	[d] Protective Orders . . . . .	10.03-15
	[3] Expert Witness Evaluation Tools . . . . .	10.03-16
	[a] Expert Interrogatories . . . . .	10.03-16
	[b] Expert Depositions and Prior Testimony . . . . .	10.03-17
	[c] Journals and Publications . . . . .	10.03-17
	[d] Expert Databases . . . . .	10.03-17
	[e] Actions by the Office of Research Integrity and the Office for Human Research Protections . . . . .	10.03-18
	[f] Other Experts . . . . .	10.03-19
	[g] Documents Produced in the Litigation . . . . .	10.03-19
	[h] The Industry Client . . . . .	10.03-19
§ 10.04	Admissibility of Expert Testimony . . . . .	10.04-1
	[1] Introduction . . . . .	10.04-1
	[2] <i>Daubert</i> Experience in Drug and Medical Device Litigation . . . . .	10.04-4
	[a] Expert Opinions Based on Epidemiological Studies and Other Human Studies . . . . .	10.04-4
	[b] Expert Opinions Based on Case Reports and Adverse Event Reports . . . . .	10.04-7
	[c] Expert Opinions Based on Animal Studies . . . . .	10.04-9
	[d] Expert Opinions Based on Similar Drugs . . . . .	10.04-11

[e] Differential Diagnosis as a Methodology for Proving Causation . . . . . 10.04-12

[f] Expert Opinions Based on Regulatory Actions . . . . . 10.04-16

[3] State Law Bases for Admissibility of Expert Testimony . . . . . 10.04-16

§ 10.05 Challenges to Qualifications . . . . . 10.05-1

§ 10.06 Expert Testimony on Regulatory Issues . . . . . 10.06-1

**CHAPTER 11**

**Trial Issues**

§ 11.01 Common Evidentiary Issues at Trial . . . . . 11.01-3

[1] Admissibility of FDA-Related Evidence . . . . . 11.01-3

[a] Manufacturer-Specific Regulatory History Documents . . . . . 11.01-3

[b] FDA Reports . . . . . 11.01-20

[c] FDA Correspondence . . . . . 11.01-22

[d] Adverse Drug and Medical Device Reports . . . . . 11.01-24

[e] Evidence of Misstatements to the FDA . . . . . 11.01-30

[f] Other FDA Evidence . . . . . 11.01-33

[2] Non-FDA Evidentiary Exclusion Issues . . . . . 11.01-37

[a] Subsequent Remedial Measures . . . . . 11.01-37

[b] Similar Incidents . . . . . 11.01-45

[c] Financial Relationships with Physicians . . . . . 11.01-52

[d] Notes of Telephone Calls by Sales Representatives . . . . . 11.01-53

[e] Corporate Motive, State of Mind, and Intent . . . . . 11.01-53

[f] Warnings, Marketing, and Other Information That Does Not Reach the Prescribing Physician . . . . . 11.01-62

[g] Foreign Regulatory Proceedings and Decisions . . . . . 11.01-64

[h] Ghostwriting . . . . . 11.01-67

[i] Other Evidentiary Issues . . . . . 11.01-68

[3] FDA Experts . . . . . 11.01-80

§ 11.02 Bifurcation and Consolidation . . . . . 11.02-1

[1] Bifurcation . . . . . 11.02-1

[a] How the Courts View Bifurcation . . . . . 11.02-1

	[b]	Types of Bifurcation . . . . .	11.02-3
		[i] General Causation . . . . .	11.02-3
		[ii] Liability . . . . .	11.02-4
		[iii] Damages . . . . .	11.02-5
		[iv] Miscellaneous . . . . .	11.02-5
	[c]	Arguments for Bifurcation . . . . .	11.02-5
		[i] Judicial Economy . . . . .	11.02-5
		[ii] Prejudice . . . . .	11.02-6
	[d]	Arguments Against Bifurcation . . . . .	11.02-7
		[i] Sterile Environment . . . . .	11.02-7
		[ii] Constitutional Limitations . . . . .	11.02-7
	[e]	Bifurcation of Punitive Damages . . . . .	11.02-9
	[2]	Consolidation . . . . .	11.02-12
§ 11.03		Punitive Damages . . . . .	11.03-1
	[1]	How the States View Punitives . . . . .	11.03-1
	[2]	Constitutional Standards Governing Punitive Damages After <i>State Farm</i> . . . . .	11.03-23
	[a]	Reprehensibility . . . . .	11.03-24
	[b]	The Range of Acceptable Punitive to Compensatory Damages Ratios . . . . .	11.03-33
	[c]	The “Comparable Civil Penalties” Assessment Is Narrowed . . . . .	11.03-51
	[d]	Evidentiary Issues After <i>State Farm</i> . . . . .	11.03-54
		[i] Evidence of Out-of-State Conduct Admissible Only If a “Nexus” to the Harm in the Action Exists . . . . .	11.03-54
		[ii] Limited Relevance of Evidence of Conduct Injurious to Nonparties . . . . .	11.03-58
		[iii] Evidence of Dissimilar Conduct Is Barred . . . . .	11.03-62
		[iv] Net Worth May be Considered, But Cannot Justify an Otherwise Unconstitutional Award . . . . .	11.03-64
		[v] Expert Testimony on the Amount of Punitive Damages Is Usually Prohibited . . . . .	11.03-68
	[e]	Conclusion . . . . .	11.03-69